Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.

2.

Oleanolic acid from grapes may increase chemotherapy effectiveness

3.

Mortality up for children with leukemia from lowest SES neighborhoods

4.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

5.

Booze and Pancreatic Cancer Risk; From 'Hospice' to 'Hope'; Gen Z-ers Skip Screening


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot